Acquired and Lost BRAF/MEK Resistance in Melanoma: A Prospective Study

Source: Cancer Therapy Advisor, March 2017

Rechallenge with dabrafenib and trametinib among patients who progressed with BRAF inhibition with or without MEK inhibition may be effective in patients with BRAFV600-mutant melanoma, according to a study published in The Lancet Oncology.1

BRAF and MEK inhibitors are effective strategies for treating BRAFV600-mutant melanoma, but tumors usually acquire treatment resistance within 1 to 3 years of treatment initiation, leading to disease progression.

For this prospective, phase 2 trial (ClinicalTrials.gov Identifier: NCT02296996), researchers enrolled 25 patients whose disease progressed with BRAF inhibition with or without MEK inhibition to receive further BRAF and MEK inhibition with dabrafenib plus trametinib. All patients discontinued prior BRAF/MEK inhibitors within 12 weeks of rechallenge initiation.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories